Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravenous USB002 to Treat Patients With Respiratory Distress Due to COVID-19 Infection

NCT04778059 is registered in ClinicalTrials.gov with US Biotest, Inc. as lead sponsor.

NCT NCT04778059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04778059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravenous USB002 to Treat Patients With Respiratory Distress Due to COVID-19 Infection
Lead sponsor
US Biotest, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
July 27, 2021
Completion date
May 10, 2022
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

2019 novel coronavirus infection, adult respiratory distress syndrome, covid-19 virus infection, respiratory distress syndrome, adult, sars coronavirus 2 infection, sars-cov-2 infection